Novel Glycosylated Dihydropyridine-Based Nanoformulations as EGFR Inhibitors

Saber, Manar M.; Khattab, Reham R.; Pasha, Sherin H.; Abd-El Wahed, Moshira M.; El-Sayed, Ahmed A.; Abdel-Rahman, Adel A-H; Nossier, Eman, S.; Hassan, Nasser A

doi:10.21608/ejchem.2025.393671.11910

	Novel Glycosylated Dihydropyridine-Based Nanoformulations as EGFR Inhibitors
Egyptian Journal of Chemistry
Articles in Press, Accepted Manuscript, Available Online from 01 September 2025
Document Type: Original Article
DOI: 10.21608/ejchem.2025.393671.11910
View on SCiNiTO
Authors
Manar M. Saber¹; Reham R. Khattab²; Sherin H. Pasha³; Moshira M. Abd-El Wahed⁴; Ahmed A. El-Sayed²; Adel A-H Abdel-Rahman¹; Eman, S. Nossier⁵; Nasser A Hassan ²
¹Department of Chemistry, Faculty of Science, Menofia University, Shbien El-Kom 32511, Egypt
²Department of Photochemistry (Synthetic Unit), Chemical Industries Research Institute, National Research Centre, 33 El Buhouth Street, P.O. Box 12622 Cairo, Egypt
³Department of Chemistry, Faculty of Science, Zagazig University, Zagazig, Egypt
⁴Department of Pathology, Faculty of Medicine, El-Menoufia University, Shebin El-Kom, Egypt
⁵Department of Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, 11754, Egypt.
Abstract
Novel pyrimido[4,5-b]quinoline-based glycosides were synthesized via ultrasound-assisted green protocols using vanillin and cycloalkanones. To enhance anticancer efficacy, selected derivatives were formulated with selenium nanoparticles (SeNPs). In vitro assays revealed potent cytotoxicity of SeNP-conjugates 4–9 against HCT-116 and HOS cancer cell lines (IC₅₀ < 0.006 μM and 0.012–0.023 μM, respectively), though similar activity against BJ-1 normal cells indicated poor selectivity. EGFR inhibition studies showed strong activity for 4-SeNPs, 9-SeNPs, and 5-SeNPs (IC₅₀ = 0.16, 0.25, and 0.32 μM), comparable to erlotinib (IC₅₀ = 0.17 μM). Molecular docking confirmed favorable binding energies (–11.63 to –10.30 kcal/mol) and key interactions with Met769, Lys721, and Arg817. ADME predictions suggested poor oral bioavailability and parenteral suitability. These findings highlight the potential of glycosylated SeNP hybrids as EGFR-targeted anticancer agents, while underscoring the need for improved selectivity and in vivo validation.
Keywords
1,4-Dihydropyridine; Glycosides; Selenium Nanoparticles (SeNPs); Nanoformulation; EGFR Inhibitors; Antiproliferative Activity and Molecular Docking


Statistics Article View: 5